| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced cancer: a robust surrogate of cancer mortality in early detection trials?
|
Sasieni, P.
|
|
|
36 |
6 |
p. 706-708
|
artikel
|
| 2 |
Advancing circulating tumor DNA detection: using whole-genome sequencing to power minimal residual disease monitoring in breast cancer
|
Andersen, L.
|
|
|
36 |
6 |
p. 609-611
|
artikel
|
| 3 |
Challenges and opportunities of emerging mechanisms of resistance to KRASG12C inhibitors
|
Cecchini, M.
|
|
|
36 |
6 |
p. 612-613
|
artikel
|
| 4 |
Corrigendum to “Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma”
|
Xu, L.X.
|
|
|
36 |
6 |
p. 709
|
artikel
|
| 5 |
ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma ☆
|
Cabezas-Camarero, S.
|
|
|
36 |
6 |
p. 660-672
|
artikel
|
| 6 |
Editorial Board
|
|
|
|
36 |
6 |
p. iii
|
artikel
|
| 7 |
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
|
Li, J.J.
|
|
|
36 |
6 |
p. 651-659
|
artikel
|
| 8 |
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
|
Westphalen, C.B.
|
|
|
36 |
6 |
p. 614-625
|
artikel
|
| 9 |
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
|
Riedl, J.M.
|
|
|
36 |
6 |
p. 682-692
|
artikel
|
| 10 |
Letter to the Editor—Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials
|
Perez, R.O.
|
|
|
36 |
6 |
p. 704-705
|
artikel
|
| 11 |
Liquid biopsy in gliomas—are we there yet?
|
Baldini, C.
|
|
|
36 |
6 |
p. 606-608
|
artikel
|
| 12 |
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody–drug conjugates arrived?
|
Papakonstantinou, A.
|
|
|
36 |
6 |
p. 603-605
|
artikel
|
| 13 |
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
|
Matulewicz, R.S.
|
|
|
36 |
6 |
p. 693-703
|
artikel
|
| 14 |
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
d’Amore, F.
|
|
|
36 |
6 |
p. 626-644
|
artikel
|
| 15 |
Redefining clinical trial strategic design to support drug approval in medical oncology
|
Antonarelli, G.
|
|
|
36 |
6 |
p. 645-650
|
artikel
|
| 16 |
Reply to the Letter to the Editor by Perez et al. regarding “Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials”
|
Garcia-Aguilar, J.
|
|
|
36 |
6 |
p. 705-706
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
36 |
6 |
p. i-ii
|
artikel
|
| 18 |
Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
|
Garcia-Murillas, I.
|
|
|
36 |
6 |
p. 673-681
|
artikel
|
Tijdschrift beschrijving